| Abigail Catellier, FNP-C | |
|
10701 Alliance Dr Ste A, Camby, IN 46113-8837 | |
| (317) 372-7328 | |
| Not Available |
| Full Name | Abigail Catellier |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Location | 10701 Alliance Dr Ste A, Camby, Indiana |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184496366 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 28233948A (Indiana) | Secondary |
| 207R00000X | Internal Medicine | 71014580A (Indiana) | Primary |
| Entity Name | Franciscan Physician Network |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225327984 PECOS PAC ID: 3072790682 Enrollment ID: O20110608000486 |
News Archive
Heart attacks are more dangerous in the morning than at any other time of day, research has shown. The study has shown that compared with other times, patients who had an attack between 6am and noon suffered around 20% more damage to their hearts. Researchers say this pattern is thought to be linked to circadian rhythms, the 24-hour "body clock" processes that influence many biological functions including blood pressure.
A failing heart's effect on the short-term memory. The impact of telephone interventions on behaviors in Latinos. Depression and heart disease. Risk factors contributing to premature coronary atherosclerosis in premenopausal women. These are just a few of the research findings that will be presented by faculty members of the UCLA School of Nursing at the American Heart Association's Scientific Sessions, being held November 12 - 16 in Orlando, FL.
Cephalon, Inc. today announced that the U.S. Food and Drug Administration (FDA) has extended the action date to March 29, 2010, for its review of the supplemental New Drug Application (sNDA) for NUVIGIL® (armodafinil) Tablets [C-IV].
Drug resistance is a major obstacle to effective treatment for patients with cancer and leukemia. Epigenetic modifying drugs have been proven effective for some patients with hematologic malignancies, such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
Celgene International Sàrl, a subsidiary of Celgene Corporation, today reported final results from the phase II portion of a multi-center phase I/II study evaluating combination therapy with REVLIMID (lenalidomide) and VIDAZA (azacitidine) in patients with higher-risk myelodysplastic syndromes (MDS) not previously treated with either drug.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Abigail Catellier, FNP-C Po Box 781076, Detroit, MI 48278-1076 Ph: (317) 528-4800 | Abigail Catellier, FNP-C 10701 Alliance Dr Ste A, Camby, IN 46113-8837 Ph: (317) 372-7328 |
News Archive
Heart attacks are more dangerous in the morning than at any other time of day, research has shown. The study has shown that compared with other times, patients who had an attack between 6am and noon suffered around 20% more damage to their hearts. Researchers say this pattern is thought to be linked to circadian rhythms, the 24-hour "body clock" processes that influence many biological functions including blood pressure.
A failing heart's effect on the short-term memory. The impact of telephone interventions on behaviors in Latinos. Depression and heart disease. Risk factors contributing to premature coronary atherosclerosis in premenopausal women. These are just a few of the research findings that will be presented by faculty members of the UCLA School of Nursing at the American Heart Association's Scientific Sessions, being held November 12 - 16 in Orlando, FL.
Cephalon, Inc. today announced that the U.S. Food and Drug Administration (FDA) has extended the action date to March 29, 2010, for its review of the supplemental New Drug Application (sNDA) for NUVIGIL® (armodafinil) Tablets [C-IV].
Drug resistance is a major obstacle to effective treatment for patients with cancer and leukemia. Epigenetic modifying drugs have been proven effective for some patients with hematologic malignancies, such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
Celgene International Sàrl, a subsidiary of Celgene Corporation, today reported final results from the phase II portion of a multi-center phase I/II study evaluating combination therapy with REVLIMID (lenalidomide) and VIDAZA (azacitidine) in patients with higher-risk myelodysplastic syndromes (MDS) not previously treated with either drug.
› Verified 5 days ago
Dianna L Boyer, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 10701 Alliance Dr Ste A, Camby, IN 46113 Phone: 317-856-7083 Fax: 317-856-7332 | |
Dr. Eric L Wymer, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 10701 Alliance Dr, Camby, IN 46113 Phone: 317-856-7083 Fax: 317-856-7332 |